Compare SBCF & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBCF | AMPH |
|---|---|---|
| Founded | 1926 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.0B |
| IPO Year | 2009 | 2005 |
| Metric | SBCF | AMPH |
|---|---|---|
| Price | $32.16 | $25.35 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $37.04 | $22.50 |
| AVG Volume (30 Days) | ★ 669.8K | 418.3K |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | ★ 10.56 | N/A |
| EPS | ★ 0.84 | 0.81 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $29.76 | $3.87 |
| Revenue Next Year | $6.28 | $4.90 |
| P/E Ratio | $38.58 | ★ $33.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.58 | $16.65 |
| 52 Week High | $36.27 | $29.52 |
| Indicator | SBCF | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 28.70 | 61.99 |
| Support Level | $30.62 | $18.51 |
| Resistance Level | $32.68 | $29.40 |
| Average True Range (ATR) | 0.66 | 1.00 |
| MACD | -0.20 | 0.08 |
| Stochastic Oscillator | 0.00 | 51.04 |
Seacoast Banking Corp of Florida is a holding company. The company provides integrated financial services, including commercial and consumer banking, wealth management, and mortgage and insurance services, to customers across Florida through branch, mobile, and online banking solutions. It maintains day-to-day operations, particularly in the areas of operations, treasury management systems, information technology, and security. The company has one reportable segment that provides these integrated financial services, with segment revenues driven mainly by interest and fees on loans, interest on cash and cash equivalents, and investment securities, and fees on depository products and services.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.